Skip to main content
APRE logo

APRE · Aprea Therapeutics, Inc. · Holdings

Track APRE — free
$0.55 +0.02 (+3.14%)
Market Cap
$6.56M
Shares
12.59M
Volume · Oct 20 366.85K Avg daily vol (3M) 288.61K

Institutional ownership from SEC Form 13F filings. Investment managers with more than $100 million in U.S. equities must disclose their positions every quarter, within 45 days of quarter-end, so the holdings shown can lag the market by up to a quarter.

Institutional holdings are being reconciled with SEC filings. Holder totals and changes may be incomplete until reconciliation finishes.
The Sep 30, 2026 filing window is still open — showing the latest known positions. Funds that have not filed yet carry their prior-quarter positions; a fund that filed without this stock counts as sold out. Each fund's Change is measured against its own previous reported quarter, shown in the Reported column. Pick a completed quarter in the Quarter selector below to put every fund on one quarter and see the stock-wide activity breakdown.
Holders: 28
Total Value: $1,901,405
Total Shares: 2,370,849

Institutional Ownership Trend

27 quarters

Holder Concentration

Across 27 13F filers
Top Holder
42.8%
Sep 2023 → Jun 2026 · range 21.9% – 45.2%
of institutional value
Top 5
82.1%
Sep 2023 → Jun 2026 · range 68.6% – 92.0%
of institutional value
Top 10
93.2%
Sep 2023 → Jun 2026 · range 93.2% – 99.3%
of institutional value
HHI
2,310
Sep 2023 → Jun 2026 · range 1,323 – 2,566
Moderately concentrated

Who Holds APRE

Last 8 quarters through Sep 30, 2026 (filing window open)

Each kind of 13F filer's share of the common shares 13F filers report. Holder type comes from regulatory records, never the filer's name; style, turnover and horizon are measured from each filer's own 13F book. The quarter selector does not change this card.

Jun 30, 2026, the newest closed quarter: 27 filers, like-for-like change +5.6%; actively managed books +7.4%; index-like books -12.1%.

Holder type Share Filers Change
Registered adviser 37.0% 9 +19.5%
Exempt adviser 11.9% 2 +4.3%
Bank 0.6% 3 +558.7%
Broker-dealer 0.7% 2 -23.1%
Non-US 1.9% 2 +13.5%
Holding company 1.4% 4 +7.1%
Adviser 0.0% 0 —
Unknown 46.5% 5 -3.7%

The Sep 30, 2026 filing window is still open, so its bar carries the Jun 30, 2026 positions of filers that have not filed yet.

How the mix is measured

Shares are 13F common shares restated to today's split basis; options and principal amounts are left out. The change compares only filers with a 13F in both quarters and keeps each filer in its bucket of the later quarter on both sides; a filer that continues under a new CIK is compared through its successor. Holder type comes from each filer's current regulatory profile; client base and private funds come from the Form ADV roster current at each quarter end (rosters from December 2019, so an earlier quarter reads Unknown). Style, turnover, horizon and book size are measured from each filer's 13F book in the newest measured quarter, and Not measured means none was. Actively managed books are those measured systematic-like, concentrated or diversified active.

Conviction and Crowding

27 13F filers, quarter ended Jun 30, 2026

Measured across every 13F filer's common-share book once the quarter's filing window closed. Crowding counts filers with high turnover or that advise private funds on Form ADV.

Conviction holders
0
0.000% of filers hold it in their top 10
Mar 31, 2026: 0
Holders above 5%
0
median weight 0.000%
Mar 31, 2026: 0
Crowding
17.2%
of shares outstanding, 50th percentile
Mar 31, 2026: 17.2%
Private-fund advisers
8.56%
of shares outstanding
Institutional ownership
19.1%
20.5% of the estimated free float
Top 10 holders
93.2%
of 13F shares, Herfindahl 0.231
Active holders
+7.4%
like-for-like share change of active filers
5% stakes on record
3
0 13D, 3 13G (3 institutional, 0 passive, 0 exempt)
How long holders have held it value-weighted 9.5 quarters
Under 1 year 29.2% 1 to 3 years 23.5% 3 years or more 47.3% Since coverage start 0.000%

Managers in the top fifth by current three-year FundScore alpha were net buyers of $0 (0 buying, 0 selling).

Estimated Holder Cost Basis

Quarter ended Jun 30, 2026, on that quarter's share basis

Estimated, never filed: each 13F buy is costed at its quarter's average traded price and each sale keeps the average cost, so this is what holders paid on average if they traded evenly through each quarter.

Estimated avg cost
$3.07
estimated per share
Mar 31, 2026: $3.36
Quarter-end price
$0.80
implied by 13F values
Estimated gain or loss
-73.9%
price against the estimated cost
Estimated at a loss
72.2%
of costed 13F value

Estimated cost covers 53.0% of the 13F shares; positions already held when a filer's 13F history starts, or bought in a quarter without a trusted average price, have no estimate.

Shared Holders

Companies APRE's active holders also own, quarter ended Jun 30, 2026
# Company Shared holders
1 VYGR Voyager Therapeutics, Inc. 3
2 TSHA Taysha Gene Therapies, Inc. 3
3 ELVN Enliven Therapeutics, Inc. 3
4 BMRN Biomarin Pharmaceutical Inc 3
5 RVMD Revolution Medicines, Inc. 3

Shareholder Targets

13F filers that own its peers but not APRE, quarter ended Jun 30, 2026

Found through its holder-overlap peers: VYGR, TSHA, ELVN, BMRN, RVMD. 956 filers in all.

# Filer In peers
1 FARALLON CAPITAL MANAGEMENT LLC Registered adviser, Diversified active $2,553,115,574 2 held
2 BAKER BROS. ADVISORS LP Registered adviser, Concentrated $2,216,322,729 3 held
3 VANGUARD PORTFOLIO MANAGEMENT LLC Registered adviser, Diversified active $2,101,116,800 5 held
4 Jupiter Topco LLC Unknown, Diversified active $2,085,006,398 4 held
5 Darwin Global Management, Ltd. Exempt adviser, Concentrated $1,990,753,064 1 held
6 STATE STREET CORP Bank, Index-like $1,506,632,348 5 held
7 Nextech Invest, Ltd. Exempt adviser, Concentrated $1,423,531,573 1 held
8 Paradigm Biocapital Advisors LP Registered adviser, Concentrated $1,191,348,571 1 held
9 NORGES BANK Non-US, Index-like $888,922,610 3 held
10 Dodge & Cox Registered adviser, Diversified active $849,426,894 1 held

Fund Ownership of APRE by Fund Type

Registered funds' Form N-PORT reports for the quarter ended Jun 30, 2026

Index funds and index ETFs hold 0.92% of shares outstanding.

Fund type Of shares outstanding Shares
Index funds 0.76% 96,073
Index ETFs 0.16% 19,622
Active ETFs 0.00% 0
Active funds 0.00% 289
Unclassified 0.00% 0
All registered funds 0.92% 115,984
How fund types are measured

Each fund series counts once, with its latest Form N-PORT report dated inside the quarter; only long share positions count, restated to today's split basis. The fund type is the series' latest Form N-CEN answer on or before the quarter end (the index-fund box and the exchange-traded flag), never its name. Unclassified funds have no usable N-CEN; unit investment trusts are among them, so index ownership is a floor. Funds sit inside their advisers' 13F reports, so these shares overlap the 13F figures and are never added to them.

Showing 28 of 28
Export CSV
Holder Value (USD) % of 13F Shares Open
Key facts CIK 1781983 CUSIP 03836J201 13F (30d) 1 filings 1 filers Visit website Investor relations